Cargando…
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these ca...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535867/ https://www.ncbi.nlm.nih.gov/pubmed/28653990 http://dx.doi.org/10.3390/ijms18071374 |
_version_ | 1783253912435818496 |
---|---|
author | Visconti, Roberta Morra, Francesco Guggino, Gianluca Celetti, Angela |
author_facet | Visconti, Roberta Morra, Francesco Guggino, Gianluca Celetti, Angela |
author_sort | Visconti, Roberta |
collection | PubMed |
description | Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer. |
format | Online Article Text |
id | pubmed-5535867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55358672017-08-04 The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy Visconti, Roberta Morra, Francesco Guggino, Gianluca Celetti, Angela Int J Mol Sci Commentary Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer. MDPI 2017-06-27 /pmc/articles/PMC5535867/ /pubmed/28653990 http://dx.doi.org/10.3390/ijms18071374 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Visconti, Roberta Morra, Francesco Guggino, Gianluca Celetti, Angela The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title | The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title_full | The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title_fullStr | The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title_full_unstemmed | The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title_short | The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy |
title_sort | between now and then of lung cancer chemotherapy and immunotherapy |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535867/ https://www.ncbi.nlm.nih.gov/pubmed/28653990 http://dx.doi.org/10.3390/ijms18071374 |
work_keys_str_mv | AT viscontiroberta thebetweennowandthenoflungcancerchemotherapyandimmunotherapy AT morrafrancesco thebetweennowandthenoflungcancerchemotherapyandimmunotherapy AT gugginogianluca thebetweennowandthenoflungcancerchemotherapyandimmunotherapy AT celettiangela thebetweennowandthenoflungcancerchemotherapyandimmunotherapy AT viscontiroberta betweennowandthenoflungcancerchemotherapyandimmunotherapy AT morrafrancesco betweennowandthenoflungcancerchemotherapyandimmunotherapy AT gugginogianluca betweennowandthenoflungcancerchemotherapyandimmunotherapy AT celettiangela betweennowandthenoflungcancerchemotherapyandimmunotherapy |